EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.

The study enrolled 59 African American patients and 56 Hispanic/Latino patients with previously untreated diabetic macular edema ... in Diabetic Retinopathy Severity Scale score vs 11.5% of ...

AMSTERDAM — The monoclonal antibody nemolizumab offers long-term efficacy and safety, as well as quality-of-life benefits, in the management of adolescents and adults with moderate to severe ...

A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema. Sonelokimab is being assessed ... and Psoriasis Area and Severity Index 90 ...

The VERONA trial is a randomized, controlled, single-masked, open-label, phase 2 study investigating Duravyu for diabetic macular edema (DME ... (OCT), and changes in diabetic retinopathy severity ...

Lower MMP-2 levels were associated with greater perihematomal edema volume and worse clinical outcome (higher NIHSS and lower Glasgow Coma Scale, GCS ... ICH onset in adults who died with presence and ...

Severe chemical pneumonia can lead to acute pulmonary edema and life-threatening acute respiratory distress ... Considering the literature reports on large-scale lung inflammation and even acute ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

A revolutionary breakthrough in cataract treatment is on the horizon, with the emergence of C-KAD, a new eye drop therapy.

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still ...